参考文献

参考文献

［1］Dasari A，Shen C，Halperin D，et al. Trends in the incidence，prevalence，and survival outcomes in patients with neuroendocrine tumors in the united states［J］.JAMA Oncol，2017，3（10）：1335-1342.

［2］Hallet J，Law CH，Cukier M，et al.Exploring the rising incidence of neuroendocrine tumors：A population-based analysis of epidemiology，metastatic presentation，and outcomes［J］.Cancer，2015，121（4）：589-597.

［3］Yao JC，Hassan M，Phan A，et al. One hundred years after“carcinoid”：Epidemiology of and prognostic factors for neuroendocrine tumors in 35，825 cases in the united states［J］.J Clin Oncol，2008，26（18）：3063-3072.

［4］Riihimaki M，Hemminki A，Sundquist K，et al.The epidemiology of metastases in neuroendocrine tumors［J］.Int J Cancer，2016，139（12）：2679-2686.

［5］Frilling A，Modlin IM，Kidd M，et al. Recommendations for management of patients with neuroendocrine liver metastases［J］.Lancet Oncol，2014，15（1）：e8-e21.

［6］Steinmüller T，Kianmanesh R，Falconi M，et al.Consensus guidelines for the management of patients with liver metastases from digestive（neuro）endocrine tumors：foregut，midgut，hindgut，and unknown primary［J］.Neuroendocrinology，2008，87（1）：47-62.

［7］Rindi G，Klöppel G，Couvelard A，et al.TNM staging of midgut and hindgut（neuro）endocrine tumors：a consensus proposal including a grading system［J］.Virchows Arch，2007，451（4）：757-762.

［8］Sutliff VE，Doppman JL，Gibril F，et al.Growth of newly diagnosed，untreated metastatic gastrinomas and predictors of growth patterns［J］.J Clin Oncol，1997，15（6）：2420-2431.

［9］Edge SB，Byrd DR，Compton CC，et al.AJCC Cancer Staging Manual［M］.7th edition.New York：Springer，2010.

［10］Amin MB，Edge SB，Greene FL，et al.AJCC Cancer Staging Manual［M］.8th edition.New York：Springer，2017.

［11］Chagpar R，Chiang YJ，Xing Y，et al.Neuroendocrine tumors of the colon and rectum：prognostic relevance and comparative performance of current staging systems［J］.Ann Surg Oncol，2013，20（4）：1170-1178.

［12］Landry CS，Brock G，Scoggins CR，et al.A proposed staging system for small bowel carcinoid tumors based on an analysis of 6，380 patients［J］.Am J Surg，2008，196（6）：896-903.

［13］Kim MK，Warner RR，Roayaie S，et al.Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors［J］.J Clin Oncol，2013，31（30）：3776-3781.

［14］Strosberg JR，Weber JM，Feldman M，et al.Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors［J］.J Clin Oncol，2013，31（4）：420-425.

［15］Kulke MH.Are neuroendocrine tumors going mainstream？［J］.J Clin Oncol，2013，31（4）：404-405.

［16］Curran T，Pockaj BA，Gray RJ，et al.Importance of lymph node involvement in pancreatic neuroendocrine tumors：impact on survival and implications for surgical resection［J］.J Gastrointest Surg，2015，19（1）：152-160.

［17］Strosberg JR，Cheema A，Weber J，et al.Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors［J］.J Clin Oncol，2011，29（22）：3044-3049.

［18］Tomassetti P，Migliori M，Simoni P，et al.Diagnostic value of plasma chromogranin A in neuroendocrine tumours［J］.Eur J Gastroenterol Hepatol，2001，13（1）：55-58.

［19］Zatelli MC，Torta M，Leon A，et al.Chromogranin A as a marker of neuroendocrine neoplasia：an Italian multicenter study［J］.Endocr Relat Cancer，2007，14（2）：473-482.

［20］Carling RS，Degg TJ，Allen KR，et al.Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease［J］.Ann Clin Biochem，2002，39（Pt 6）：577-582.

［21］Kwekkeboom DJ，Krenning EP，Scheidhauer K，et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors：somatostatin receptor imaging with（111）in-pentetreotide［J］.Neuroendocrinology，2009，90（2）：184-189.

［22］Kumbasar B，Kamel IR，Tekes A，et al.Imaging of neuroendocrine tumors：accuracy of helical CT versus SRS［J］.Abdom Imaging，2004，29（6）：696-702.

［23］Rockall AG，Planche K，Power N，et al.Detection of neuroendocrine liver metastases with MnDPDP-enhanced MRI ［J］.Neuroendocrinology，2009，89（3）：288-295.

［24］WHO.WHO Classification of Tumours of Endocrine Organs［M］.Vol.10（ed 4）.Lyon，France：International Agency for Research on Cancer（IARC），2017.

［25］Rindi G，Kloppel G，Couvelard A，et al.TNM staging of midgut and hindgut（neuro）endocrine tumors：a consensus proposal including a grading system［J］.Virchows Arch，2007，451（4）：757-762.

［26］Marx A，Shimosato Y，Kuo TT，et al. Thymic neuroendocrine tumours［M］.In：Travis WD BE，Muller-Hermelink HK，Harris CC，et al.WHO Classification of Tumours of the Lung，Pleura，Thymus and Heart.Lyon：IARC，2004.

［27］Chamberlain RS，Canes D，Brown KT，et al.Hepatic neuroendocrine metastases：does intervention alter outcomes？［J］.J Am Coll Surg，2000，190（4）：432-445.

［28］McEntee GP，Nagorney DM，Brown KT，et al.Cytoreductive hepatic surgery for neuroendocrine tumors［J］.Surgery，1990，108（6）：1091-1096.

［29］Sarmiento JM，Heywood G，Rubin J，et al.Surgical treatment of neuroendocrine metastases to the liver：a plea for resection to increase survival［J］.J Am Coll Surg，2003，197（1）：29-37.

［30］Glazer ES，Tseng JF，Al-Refaie W，et al.Long-term survival after surgical management of neuroendocrine hepatic metastases［J］.HPB（Oxford），2010，12（6）：427-433.(https://www.daowen.com)

［31］Mayo SC，de Jong MC，Pulitano C，et al.Surgical management of hepatic neuroendocrine tumor metastasis：results from an international multi-institutional analysis［J］.Ann Surg Oncol，2010，17（12）：3129-3136.

［32］Frilling A，Modlin IM，Kidd M，et al. Recommendations for management of patients with neuroendocrine liver metastases［J］.Lancet Oncol，2014，15（1）：e8-e21.

［33］Cidon EU. New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors：A glimpse into the future［J］.World J Gastrointest Oncol，2017，9（1）：4-20.

［34］Rossi RE，Ciafardini C，Sciola V，et al.Chromogranin A in the followup of gastroenteropancreatic neuroendocrine neoplasms：is it really game over？a systematic review and meta-analysis［J］.Pancreas，2018，47（10）：1249-1255.

［35］Mazzaferro V，Sposito C，Coppa J，et al.The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors［J］.Am J Transplant，2016，16（10）：2892-2902.

［36］American Joint Committee on Cancer.AJCC cancer staging manual［M］.8th edition.Chicago IL：Springer，2017.

［37］Le Treut YP，Gregoire E，Klempnauer J，et al.Liver transplantation for neuroendocrine tumors in Europe results and trends in patient selection：a 213-case European liver transplant registry study［J］.Ann Surg，2013，257（5）：807-815.

［38］Clift AK，Frilling A.Management of patients with hepatic metastases from neuroendocrine tumors［J］.Ann Saudi Med，2014，34（4）：279-290.

［39］Alagusundaramoorthy SS，Gedaly R. Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor［J］.World J Gastroenterol，2014，20（39）：14348-14358.

［40］Fan ST，Le Treut YP，Mazzaferro V，et al.Liver transplantation for neuroendocrine tumour liver metastases［J］.HPB（Oxford），2015，17（1）：23-28.

［41］Berber E，Flesher N，Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases［J］.World J Surg，2002，26（8）：985-990.

［42］Mazzaglina PJ，Berber E，Milas M，et al.Laparoscopic radiofrequency ablation of neuroendocrine liver metastases：a 10-year experience evaluation predictors of survival［J］.Surgery，2007，142（1）：10-19.

［43］Taner T，Atwell TD，Zhang L，et al. Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection［J］.HPB（Oxford），2013，15（3）：190-195.

［44］Rinke A，Müller HH，Schade-Brittinger C，et al.Placebo-controlled，doubleblind，prospective，randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors：a report from the PROMID study group［J］.J Clin Oncol，2009，27（28）：4656-4663.

［45］Caplin ME，Pavel M，Ćwikła JB，et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors［J］.N Engl J Med，2014，371（3）：224-233.

［46］Rinke A，Wittenberg M，Schade-Brittinger C，et al. Placebocontrolled，double blind，prospective，randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors（PROMID）：results on longterm survival［J］.Neuroendocrinology，2017，104（1）：26-32.

［47］Yao JC，Phan AT，Chang DZ，et al.Efficacy of RAD001（everolimus）and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors：results of a phaseⅡstudy［J］.J Clin Oncol，2008，26（26）：4311-4318.

［48］Pavel ME，Hainsworth JD，Baudin E，et al.Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome（RADIANT-2）：a randomised，placebo-controlled，phase 3 study［J］.Lancet，2011，378（9808）：2005-2012.

［49］Pavel ME，Baudin E，Oberg KE，et al.Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome：final overall survival from the randomized，placebocontrolled phase 3 RADIANT-2 study［J］.Ann Oncol，2017，28（7）：1569-1575.

［50］Raymond E，Dahan L，Raoul JL，et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors［J］.N Engl J Med，2011，364（6）：501-513.

［51］Strosberg JR，Wolin EM，Chasen B. NETTER-1 phaseⅢ：progression-free survival，radiographic response，and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177Lu-Dotatate［J］.J Clin Oncol，2016，34（Suppl 4S）：13.

［52］Norton JA，Warren RS，Kelly MG，et al.Aggressive surgery for metastatic liver neuroendocrine tumors［J］.Surgery，2003，134（6）：1057-1063.

［53］Kouvaraki MA，Ajani JA，Hoff P，et al.Fluorouracil，doxorubicin，and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas［J］.J Clin Oncol，2004，22（23）：4762-4771.

［54］Kulke MH，Stuart K，Enzinger PC，et al. PhaseⅡ study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors［J］.J Clin Oncol，2006，24（3）：401-406.

［55］Fjällskog ML，Granberg DP，Welin SL，et al.Treatment with cisplatin and etoposide in patients with neuroendocrine tumors［J］.Cancer，2001，92（5）：1101-1107.

［56］Bajetta E，Catena L，Procopio G，et al. Are capecitabine and oxaliplatin（XELOX）suitable treatments for progressing low-grade and high-grade neuroendocrine tumours？［J］. Cancer Chemother Pharmacol，2007，59（5）：637-642.

［57］Sun W，Lipsitz S，Catalano P，et al.PhaseⅡ／Ⅲstudy of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors：Eastern Cooperative Oncology Group Study E1281［J］.J Clin Oncol，2005，23（22）：4897-4904.

［58］Mitry E，Walter T，Baudin E，et al.Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal（GI-NETs）tract（BETTER trial）-a phaseⅡnon-randomised trial［J］.Eur J Cancer，2014，50（18）：3107-3115.

［59］Kunz PL，Balise RR，Fehrenbacher L，et al. Oxaliplatin fluoropyrimidine chemotherapy plus bevacizumab in advanced neuroendocrine tumors：an analysis of 2 phaseⅡtrials［J］.Pancreas，2016，45（10）：1394-1400.